Search research articles
Contact Us
Filters
Showing results (171-180 of 213) with videos related to
Page
of 22
Sort By:
JACC. Cardiooncology
|
August 14, 2025
Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy
Evaline Cheng, Maja Ivanovic, Antonia Chan, et al.
Circulation. Heart Failure
|
December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial
Sanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
European Journal of Heart Failure
|
October 17, 2022
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum
Javed Butler, Muhammad Shariq Usman, Kevin J Anstrom, et al.
The New England Journal of Medicine
|
November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Journal of Cardiac Failure
|
April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Eugene Braunwald, et al.
JACC. Heart Failure
|
June 10, 2025
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials
Mats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
Journal of Cardiac Failure
|
April 24, 2022
Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial
Bradi B Granger, Lisa A Kaltenbach, Gregg C Fonarow, et al.
Circulation
|
November 20, 2014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial
Marc A Pfeffer, Brian Claggett, Susan F Assmann, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 21, 2025
Sacubitril/valsartan and Quality of Life Assessed Using the EuroQol 5-Dimension 3-Level Questionnaire Level Sum Score (EQ-5D-3L-LSS) in Patients with HFrEF and HFmrEF/HFpEF
Mingming Yang, Alasdair D Henderson, Inder S Anand, et al.
Page
of 22
Search research articles
Search
Showing results (171-180 of 213) with videos related to
Sort By:
Page
of 22
JACC. Cardiooncology
|
August 14, 2025
Cardiac Troponin Screening and Clinical Outcomes in Patients Receiving Immunotherapy
Evaline Cheng, Maja Ivanovic, Antonia Chan, et al.
Circulation. Heart Failure
|
December 22, 2012
Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial
Sanjiv J Shah, John F Heitner, Nancy K Sweitzer, et al.
European Journal of Heart Failure
|
October 17, 2022
Soluble guanylate cyclase stimulators in patients with heart failure with reduced ejection fraction across the risk spectrum
Javed Butler, Muhammad Shariq Usman, Kevin J Anstrom, et al.
The New England Journal of Medicine
|
November 3, 2009
A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease
Marc A Pfeffer, Emmanuel A Burdmann, Chao-Yin Chen, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation
|
December 23, 2018
Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT)
Finnian R Mc Causland, Brian Claggett, Emmanuel A Burdmann, et al.
Journal of Cardiac Failure
|
April 18, 2025
NT-proBNP in the Early Convalescent Phase after High-Risk Myocardial Infarction Is Associated with Adverse Cardiovascular Outcomes: the PARADISE-MI Trial
Karola S Jering, Brian L Claggett, Eugene Braunwald, et al.
JACC. Heart Failure
|
June 10, 2025
Obesity and Risk of Kidney Outcomes in Heart Failure With Preserved Ejection Fraction: A Participant-Level Pooled Analysis of 4 Contemporary Trials
Mats C H Lassen, John W Ostrominski, Brian L Claggett, et al.
Journal of Cardiac Failure
|
April 24, 2022
Health System-Level Performance in Prescribing Guideline-Directed Medical Therapy for Patients With Heart Failure With Reduced Ejection Fraction: Results From the CONNECT-HF Trial
Bradi B Granger, Lisa A Kaltenbach, Gregg C Fonarow, et al.
Circulation
|
November 20, 2014
Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial
Marc A Pfeffer, Brian Claggett, Susan F Assmann, et al.
European Heart Journal. Cardiovascular Pharmacotherapy
|
August 21, 2025
Sacubitril/valsartan and Quality of Life Assessed Using the EuroQol 5-Dimension 3-Level Questionnaire Level Sum Score (EQ-5D-3L-LSS) in Patients with HFrEF and HFmrEF/HFpEF
Mingming Yang, Alasdair D Henderson, Inder S Anand, et al.
Page
of 22